Skeletal muscle glucose uptake in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy
Recruiting
- Conditions
- CM
- Registration Number
- NL-OMON29160
- Lead Sponsor
- Radboudumc, Nijmegen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 45
Inclusion Criteria
Age: =18 years
Fasting glucose level: = 6,0 mmol/l
?
Specifically for CML patients:
- Nilotinib treatment for at least 6 months prior to study inclusion OR
- Imatinib treatment for at least 6 months prior to study inclusion
Exclusion Criteria
Contra-indication to exercise testing according to the ACC/AHA guidelines
Incapable to provide informed consent
?
Specifically for subgroup op participants undergoing [18F]FDG PET/CT scanning:
- Renal dysfunction with MDRD <60
- Known prior allergic reaction to [18F]FDG
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Differences in area under the curve (AUC) of glucose disappearance upon a single glucose bolus after an exercise bout.
- Secondary Outcome Measures
Name Time Method Standard uptake value (SUV) of [18F]FDG as determined on PET/CT images.